Skip to main content
. Author manuscript; available in PMC: 2021 Feb 5.
Published in final edited form as: Nature. 2020 Aug 5;586(7830):567–571. doi: 10.1038/s41586-020-2622-0

Extended Data Figure 9. mRNA-1273 protects mice from upper and lower airway SARS-CoV-2 infection, 13 weeks post-boost.

Extended Data Figure 9.

BALB/cJ mice were immunized at weeks 0 and 3 with 0.01 (green), 0.1 (blue), or 1 μg (red) of mRNA-1273. Age-matched naive mice (gray) served as controls. Thirteen weeks post-boost, mice were challenged with mouse-adapted SARS-CoV-2. Two days post-challenge, at peak viral load, mouse lungs (a) and nasal turbinates (b) were harvested from 5 mice per group (3 mice for the 1 μg group) for analysis of viral titers. All dose levels were compared by Kruskal-Wallis ANOVA with Dunn’s multiple comparisons test. * = p-value < 0.05. Data are presented as GMT +/− geometric SD. Dotted line represents assay limit of detection.